



Bricanyl Turbuhaler advertisement.

[s.l.]: [s.n.], 2025-12-29

<https://digital.library.wisc.edu/1711.dl/6FBQ2FX6KAHAN8F>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.



Effective teamwork

– for rapid relief of asthma symptoms

Bricanyl® Turbuhaler® combines the clinical efficacy of terbutaline with an inspiratory flow driven multidose inhaler.

A dependable team from Astra.

Bricanyl Turbuhaler (terbutaline sulphate dry powder inhaler). Abbreviated Prescribing Information. See local Prescribing Information for full details, as Prescribing Information may vary from country to country.

Properties: Inhaled adrenergic agonist which predominantly stimulates beta-2-receptors, thus producing relaxation of bronchial smooth muscle.

Indications: Bronchial asthma. Chronic bronchitis, emphysema and other lung diseases where bronchospasm is a complicating factor.

Contra-indications: Hypersensitivity to terbutaline.

Dosage: Should be used as required rather than regularly. Dosage is individual. Adults and children over 12 years: 0.25-0.50 mg as required. Single doses may be increased to 1.5 mg. Total dose in 24 hours should not exceed 6 mg. Children 3-12 years: 0.25-0.50 mg as required. Single doses may be increased to 1 mg. Total dose in 24 hours should not exceed 4 mg.

Warnings and Precautions: Caution in patients with hyperthyroidism that is not yet adequately controlled. Caution when starting asthmatics with concomitant diabetes on Bricanyl. Concomitant treatment with xanthines, steroids or diuretics may potentiate hypokalemia. Should not be used in patients with hypertrophic cardiomyopathy.

Note: The patient should seek medical advice if a previously effective dosage regimen no longer gives the same relief.

Side effects: Most common: tremor, palpitations. Usually tolerance is developed within 1-2 weeks. Urticaria and exanthema may occur. In rare cases, through unspecified mechanisms, drugs for inhalation may cause bronchospasm.

Interactions: The effect of beta-agonists may be inhibited by beta-receptor blocking agents (especially those which are non-selective). Legal category: POM. Further information is available on request from Astra Draco AB or the local Astra company.

ASTRA

Astra Draco AB, P.O. Box 34, S-221 00 Lund, Sweden.



Bricanyl Turbuhaler® is a registered trademark owned by Astra AB. Other trademarks are Bricanyl® Turbuhaler®, Aerodur® Turbuhaler®, Bricalin® Turbuhaler®, [®]Turbuhaler® and Terbasmin® Turbuhaler®.